SCHEMBL6067966

SCHEMBL6067966

N#Cc1ccc2nc(NC(=O)S)sc2c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 7/20 0.76
▸ GSK3B P49841 1/20 0.56
▸ PIK3CG P48736 1/20 0.53
▸ CSNK1D P48730 1/20 0.52
▸ CSNK1G2 P78368 1/20 0.52
▸ ABL1 P00519 1/20 0.51
▸ PDE4B Q07343 1/20 0.50
▸ ITK Q08881 1/20 0.49
▸ RAB9A P51151 3/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ CYP1A2 P05177 2/20 0.47
▸ CYP3A4 P08684 2/20 0.47
▸ CYP2C19 P33261 2/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ FSCN1 Q16658 1/20 0.47
▸ PDPK1 O15530 1/20 0.47
▸ ACP1 P24666 2/20 0.46
▸ APP P05067 2/20 0.46
▸ ADORA2A P29274 1/20 0.46
▸ ADORA1 P30542 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21568692 0.86 DYRK1A (1.00) DYRK1AGSK3BPIK3CGCSNK1DCSNK1G2
SCHEMBL13718453 0.83 DYRK1A (0.74) DYRK1AGSK3BPIK3CGCSNK1DCSNK1G2
SCHEMBL6067971 0.82 DYRK1A (0.69) DYRK1AGSK3BPIK3CGCSNK1DCSNK1G2
SCHEMBL23256870 0.81 DYRK1A (0.70) DYRK1AGSK3BCSNK1DCSNK1G2RAB9A
SCHEMBL6068126 0.81 DYRK1A (0.71) DYRK1AGSK3BPIK3CGABL1RAB9A
SCHEMBL21568049 0.81 DYRK1A (0.76) DYRK1AGSK3BPIK3CGCSNK1DCSNK1G2
SCHEMBL23256883 0.80 DYRK1A (0.66) DYRK1AGSK3BCSNK1DCSNK1G2RAB9A
SCHEMBL21568123 0.79 DYRK1A (0.65) DYRK1AGSK3BCSNK1DCSNK1G2RAB9A
SCHEMBL21568323 0.79 DYRK1A (0.65) DYRK1AGSK3BCSNK1DCSNK1G2RAB9A
SCHEMBL23256895 0.79 DYRK1A (0.68) DYRK1AGSK3BCSNK1DCSNK1G2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7091227-B2 Benzothiazole derivatives ABBOTT GMBH & CO. KG (DE) 2006-08-15 — — US disclosed
US-20030153568-A1 Benzothiazole derivatives BASF AKTIENGESELLSCHAFT LUDWIGSHAFEN, GERMANY 2003-08-14 — — US disclosed
EP-1254123-A1 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS Abbott GmbH & Co. KG (DE) 2002-11-06 — — EP disclosed
WO-2001057008-A1 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) 2001-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153568-A1 Benzothiazole derivatives TK1, FLT1, CDK1 DYRK1A 231/4885GSK3B 89/4885PIK3CG 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback